Celon Biology: Net profit in 2025 was RMB 51.7135 million, a year-on-year increase of 16.76%.

Selon Biological released its interim report, achieving a total operating income of 196 million yuan in 2025, a year-on-year increase of 0.66%; achieving a net profit attributable to the owners of the parent company of 51.7135 million yuan, a year-on-year increase of 16.76%. During the reporting period, the company's operating income slightly increased, and the gross profit margin remained basically stable. The rabies serum that was listed for sale online in the second half of 2025 is still in the initial stage of sales and has not yet made a significant contribution to income in the reporting period. The increase in net profit for the period is mainly due to the company recognizing investment losses in its equity joint venture Shanghai Saixuan Biotechnology Co., Ltd. in 2024 and providing full impairment provision for the balance of long-term equity investments, as well as the decrease in non-recurring gains and losses and research and development expenses in this period compared to the previous year.